RxDoctor Payments Data

Brooke Holden

Family · Hot Springs, ARNPI 1598205320

Payments from drug & device makers

$5,897in general payments, 2019–2025

Across 264 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Gilead$474
  • Janssen Scientific Affairs, LLC$286
  • Merck$222
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$217
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,58795%
  • Education$3105%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,897 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$61,451
Medicare patients
496
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide57$55,933
CreonLipase/Protease/Amylase12$38,904
SutabSod Sulf/Pot Chloride/Mag Sulf51$8,246
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C58$8,031
Pantoprazole Sodium403$4,488
MovantikNaloxegol Oxalate11$4,352
Sucralfate94$3,623
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag27$3,270
Famotidine235$2,825
Balsalazide Disodium16$1,960
Omeprazole96$1,250
Dicyclomine Hcl73$1,239
Colestipol Hcl28$930
Lansoprazole28$896
Ondansetron OdtOndansetron64$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,829$94,83769 claims
Braintree Laboratories, Inc.Sutab, Suflave$59$11,51678 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$217$8,03158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →